Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07177196 · ClinicalTrials.gov registry record · Phase 1
Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy
A Phase 1 study of Retinal Dystrophy, sponsored by n-Lorem Foundation.
- Active
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT07177196: Active Phase 1 study of Retinal Dystrophy, sponsored by n-Lorem Foundation.
NCT07177196 is a Phase 1 study of Retinal Dystrophy that is active but no longer recruiting, run by n-Lorem Foundation. The registered enrollment target is 1 participants, below the 37-participant average among 3 other Retinal Dystrophy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07177196, a Phase 1 study of Retinal Dystrophy, is active but no longer recruiting, sponsored by n-Lorem Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Retinal Dystrophy due to PRPH2 mutation
Primary Outcome
Incidence and severity of treatment emergent ocular adverse events (TEAEs) and serious ocular adverse events
Conditions Studied
Interventions
- DRUG nL-PRPH2-001
Study Locations (1)
California
- University of California San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What the registry record for NCT07177196 still lists
NCT07177196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 37-participant average among 3 other Retinal Dystrophy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Retinal Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which nL-PRPH2-001 is the first listed.
NCT07177196 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07177196 about?
NCT07177196 is a clinical study titled "Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy". This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Retinal Dystrophy due to PRPH2 mutation
What is the current status of trial NCT07177196?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2025-08-28. Estimated completion is 2027-08.
What conditions does trial NCT07177196 study?
This clinical trial studies the following conditions: Retinal Dystrophy.
What interventions are being tested in trial NCT07177196?
The interventions under investigation include: nL-PRPH2-001 (DRUG).
Who is sponsoring clinical trial NCT07177196?
This trial is sponsored by n-Lorem Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07177196 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI